NCI-2020-06147

MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types

This is a Phase 1/2 multicenter, open-label trial evaluating the safety, tolerability, and efficacy of a new drug called MORAb-202. The study aims to assess the safety profile of MORAb-202 and determine its effectiveness in treating specific tumor types that express FRα.

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04300556

Clinical Trial Site: Columbia

To see all available clinical trials click here.